Annual Summary of Disease Activity:
Disease Control Newsletter (DCN)
- DCN Home
- Annual Summary, 2022
- Annual Summary, 2021
- Annual Summary, 2020
- Annual Summary, 2019
- Annual Summary, 2018
- Annual Summary, 2017
- Annual Summary, 2016
- Annual Summary, 2015
- Annual Summary, 2014
- Annual Summary, 2013
- Annual Summary, 2012
- Annual Summary, 2011
- Annual Summary, 2010
- Annual Summary, 2009
- Annual Summary, 2008
- Annual Summary, 2007
- Annual Summary, 2006
- Annual Summary, 2005
- Annual Summary, 2004
- Annual Summary, 2003
- Annual Summary, 2002
- Annual Summary, 2001
- Annual Summary, 2000
- Annual Summary, 1999
- Annual Summary, 1998
- Annual Summary, 1997
Related Topics
Contact Info
Meningococcal Disease, 2018
For the first time ever, there were no Neisseria meningitidis (NM) invasive disease cases in 2018. There were 5 cases in 2017, and 5 cases in 2016. Incidence of invasive NM was stable at about 0.30 cases per 100,000 persons since 2005 (with the exception of 2008 when incidence increased to 0.57 cases per 100,000 persons); however, invasive NM incidence has decreased since 2011. The quadrivalent conjugate vaccine, MenACWY is recommended at 11- 12 years with a booster at age 16. Vaccination rates for at least 1 dose among 13-17 year old Minnesota adolescents is 78.5%; rates for the booster are lagging at 26.9% (Minnesota Immunization Information Connection, 2018 data). Meningococcal B vaccine is recommended for persons 10 years of age and older with specific risk factors. It should especially be considered for those 16-23 years of age, especially in outbreak situations.
- For up to date information see>> Meningococcal Disease
- Full issue>> Annual Summary of Communicable Diseases Reported to the Minnesota Department of Health, 2018